Endocrinology

Reports of high-impact endocrinology studies by medical professionals

Mixed cardiovascular benefit with PCSK9 inhibitior bococizumab: The SPIRE trial

1. When added to statin therapy, the proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor bococizumab significantly reduced the risk of cardiovascular events in patients...

Significant decline in mortality related to diabetes from 1998 to 2014

1. In a large Swedish registry-cohort study, the authors report significant declines in all-cause mortality and diabetes-related complications in patients with both type 1...

Benefits and harms of osteoporosis medications unclear for patients with CKD

1. While osteoporosis medications may have some benefits in chronic kidney disease patients (CKD), the evidence is unclear with respect to their impact on...

Trends in thyroid cancer incidence and mortality in the United States from 1974-2013

1. This ecological study found that from 1974 to 2013, there were average annual increases in incidence rates and mortality rates in patients diagnosed...

Weight fluctuations associated with mortality in patients with coronary artery disease

1. In patients with coronary artery disease (CAD), increased body-weight variability demonstrated a graded increased risk of cardiovascular events and death. 2. The association of...

Being overweight at any point in adulthood increases risk for death

1. Maximum BMIs in overweight, obese, and obese II categories were associated with increases in risk for all-cause mortality. 2. This relationship between BMI and...

Body weight may not be the best way to assess cardiometabolic risk in some...

1. All racial/ethnic minority groups evaluated, compared with Caucasian patients, had a statistically higher prevalence of metabolic abnormality but normal body weight (MAN). 2. Using...

A virtual glucose management service significantly improved glycemic control in hospitalized patients

1. Implementation of the virtual glucose management service reduced the number of severe hypoglycemic events experienced by hospitalized adult inpatients. 2. The proportion of both...

Evolocumab demonstrated to have long-term efficacy at lowering low-density lipoprotiein: The Osler-1 trial

1. This multi-year, open-label extension of phase 2 trials examining the LDL-lowering efficacy of evolocumab (PCSK9-inhibitor) showed that evolocumab plus standard of care lipid...

Suboptimal dietary habits linked to deaths from heart disease, stroke, and type 2 diabetes

1. Over 45% of deaths due to heart disease, stroke, and type 2 diabetes in US adults in 2012 was due to suboptimal dietary...
licensing as small

Popular